<i>POLRMT</i> as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients
Anthracyclines are among the most used chemotherapeutic agents in breast cancer (BC). However their use is hampered by anthracycline-induced cardiotoxicity (AIC). The currently known clinical and genetic risk factors do not fully explain the observed inter-individual variability and only have a limi...
Saved in:
Main Authors: | Alejandro Velasco-Ruiz (Author), Rocio Nuñez-Torres (Author), Guillermo Pita (Author), Hans Wildiers (Author), Diether Lambrechts (Author), Sigrid Hatse (Author), Danielle Delombaerde (Author), Thomas Van Brussel (Author), M. Rosario Alonso (Author), Nuria Alvarez (Author), Belen Herraez (Author), Christof Vulsteke (Author), Pilar Zamora (Author), Teresa Lopez-Fernandez (Author), Anna Gonzalez-Neira (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protective effect of propolis from Tigzirt on epirubicin-induced cardiotoxicity and nephrotoxicity.
by: Sara Chaa, et al.
Published: (2021) -
Polyphosphazene-Based Nanocarriers for the Release of Camptothecin and Epirubicin
by: Javier Pérez Quiñones, et al.
Published: (2022) -
Function of Epirubicin-Conjugated Polymeric Micelles in Sonodynamic Therapy
by: Kazuhisa Takemae, et al.
Published: (2019) -
Melatonin protects against Epirubicin-induced ovarian damage
by: Naiqiang WANG, et al.
Published: (2019) -
Lysine Decorated Solid Lipid Nanoparticles of Epirubicin for Cancer Targeting and Therapy
by: Parvaneh Bayat, et al.
Published: (2021)